Emerging Markets Earnings Roundup: GSK (Part 9)
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline executives spoke to the point about continued sales issues in China, but offered some guidance that its issues with a compliance scandal that started in July last year are stabilizing. CEO Andrew Witty spent much of his time talking about the massive deal with Novartis, leaving Simon Dingemans, chief financial officer, to fill in details on emerging markets.